Oncoc4, Inc.
Clinical trials sponsored by Oncoc4, Inc., explained in plain language.
-
New combo shows promise for tough prostate cancer
Disease control OngoingThis study tests a combination of two drugs (ONC-392 and a radioactive therapy) in men with advanced prostate cancer that has stopped responding to hormone therapy. About 148 participants will be randomly assigned to receive the combo or standard care. The goal is to see if the c…
Phase: PHASE1, PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated May 26, 2026 08:38 UTC
-
New immunotherapy cocktail targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment. The goal is to find the safest dose and see if it can shrink tumors in people with advanced cancers like melanoma, lung, and ovarian canc…
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated May 26, 2026 08:36 UTC
-
New hope for tough ovarian cancer: drug combo trial launches
Disease control OngoingThis study tests a combination of two drugs, ONC-392 and pembrolizumab, in 58 women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the combo can shrink tumors and control the disease. Participants must have a specific type of…
Phase: PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated May 26, 2026 08:30 UTC